



[Go to Product page](#)

Datasheet for ABIN5668216

## Recombinant anti-CD22 (Epratuzumab Biosimilar) antibody

### Overview

Quantity:	200 µg
Target:	CD22 (Epratuzumab Biosimilar)
Reactivity:	Human, Cynomolgus, Rhesus Monkey
Host:	Human
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Application:	Flow Cytometry (FACS), Immunoprecipitation (IP), Blocking Peptide (BP)

### Product Details

Immunogen:	This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
Clone:	HL22
Isotype:	IgG1 kappa
Specificity:	This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
Characteristics:	OriginalSpeciesName: Human OriginalFormat: IgG1
Purification:	Purified antibody.
Purity:	> 98 % as determined by SDS-PAGE

## Product Details

---

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

## Target Details

---

Target: CD22 (Epratuzumab Biosimilar)

Target Type: Biosimilar

Background: Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14

UniProt: [P20273](#)

## Application Details

---

Application Notes: Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Restrictions: For Research Use only

## Handling

---

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C, -20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.